Positive News Sentiment NASDAQ:DFFN Diffusion Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Diffusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.89 -0.15 (-2.13%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$6.80▼$7.2550-Day Range$5.66▼$8.2152-Week Range$5.10▼$34.31Volume4,369 shsAverage Volume31,625 shsMarket Capitalization$14.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Diffusion Pharmaceuticals MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.82) to ($6.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.79 out of 5 starsMedical Sector1144th out of 1,433 stocksPharmaceutical Preparations Industry556th out of 683 stocks 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Diffusion Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.62% of the float of Diffusion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDiffusion Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Diffusion Pharmaceuticals has recently decreased by 15.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDiffusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthDiffusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DFFN. Previous Next 2.7 News and Social Media Coverage News SentimentDiffusion Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for DFFN on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diffusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Diffusion Pharmaceuticals is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Diffusion Pharmaceuticals are expected to grow in the coming year, from ($7.82) to ($6.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Diffusion Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diffusion Pharmaceuticals is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiffusion Pharmaceuticals has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DFFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Diffusion Pharmaceuticals (NASDAQ:DFFN) StockDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.Read More DFFN Stock News HeadlinesJune 23, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces Positive Effects in Altitude TrialJune 15, 2022 | americanbankingnews.comDiffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Sees Significant Decline in Short InterestMay 20, 2022 | finance.yahoo.comDFFN: Data from Altitude Trial Expected in June 2022…May 18, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory OfficerMay 17, 2022 | finance.yahoo.comDiffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment ConferenceMay 14, 2022 | seekingalpha.comDiffusion Pharmaceuticals GAAP EPS of -$2.22May 13, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 4, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Regains Compliance With Nasdaq Listing RequirementsApril 19, 2022 | markets.businessinsider.com5 Stocks Halted In Tuesday's SessionApril 19, 2022 | nasdaq.comDiffusion Pharma Falls 18% After Announcing Reverse Stock SplitApril 19, 2022 | finanznachrichten.deDiffusion Pharmaceuticals Inc.: Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance PlanApril 18, 2022 | uk.investing.comWhy Diffusion Pharmaceuticals Shares Are FallingApril 18, 2022 | seekingalpha.comDiffusion Pharma crashes after announcing reverse stock splitApril 18, 2022 | finance.yahoo.comDiffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect TomorrowApril 18, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance PlanApril 11, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Completes Dosing in Altitude TrialApril 8, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of StockholdersApril 8, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of StockholdersMarch 23, 2022 | finance.yahoo.comDFFN: Additional Tissue Oxygenation Trial Results Expected Mid-2022…March 21, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business UpdateMarch 9, 2022 | finance.yahoo.comWe're Keeping An Eye On Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn RateFebruary 24, 2022 | finance.yahoo.comDiffusion Pharmaceuticals Expands its Scientific Advisory Board with the Addition of Leading Radiation and Medical Oncology ExpertsDecember 20, 2021 | finance.yahoo.comDiffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”December 16, 2021 | finance.yahoo.comDiffusion Pharmaceuticals Doses First Patients in ILD-DLCO TrialDecember 1, 2021 | finance.yahoo.comDiffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DFFN CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone(434) 220-0718Fax434-220-0722Employees16Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/06/2022Next Earnings (Estimated)8/10/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($12.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.35% Return on Assets-58.13% Debt Debt-to-Equity RatioN/A Current Ratio11.36 Quick Ratio11.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.13 per share Price / Book0.40Miscellaneous Outstanding Shares2,040,000Free Float2,002,000Market Cap$14.06 million OptionableNot Optionable Beta1.64 Diffusion Pharmaceuticals Frequently Asked Questions Should I buy or sell Diffusion Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Diffusion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DFFN, but not buy additional shares or sell existing shares. View analyst ratings for Diffusion Pharmaceuticals or view top-rated stocks. How has Diffusion Pharmaceuticals' stock price performed in 2022? Diffusion Pharmaceuticals' stock was trading at $15.25 on January 1st, 2022. Since then, DFFN shares have decreased by 54.8% and is now trading at $6.89. View the best growth stocks for 2022 here. When is Diffusion Pharmaceuticals' next earnings date? Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022. View our earnings forecast for Diffusion Pharmaceuticals. How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) announced its earnings results on Thursday, May, 12th. The company reported ($2.22) EPS for the quarter, missing analysts' consensus estimates of ($1.75) by $0.47. View Diffusion Pharmaceuticals' earnings history. When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work? Diffusion Pharmaceuticals's stock reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 19th 2022. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 2 shares after the split. Who are Diffusion Pharmaceuticals' key executives? Diffusion Pharmaceuticals' management team includes the following people: Dr. Robert J. Cobuzzi Jr., Pres, CEO & Director (Age 57, Pay $1.23M)Mr. William Karl Hornung, Chief Financial Officer (Age 53, Pay $450.68k)Mr. William Robert Elder J.D., Gen. Counsel & Corp. Sec. (Age 39, Pay $338.36k)Dr. Christopher D. Galloway M.D., Chief Medical Officer (Age 51, Pay $539.59k)Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 59)Ms. Suzanne Cassidy, Sr. Director & Head of Quality AssuranceDr. Jennifer Llewelyn Ph.D., Sr. Director & Head of CMCMs. Raven Jaeger M.S., Chief Regulatory OfficerMs. Kelly Hoy, Director of Project ManagementMr. Harry Cook, VP of Clinical Operations Who are some of Diffusion Pharmaceuticals' key competitors? Some companies that are related to Diffusion Pharmaceuticals include 9 Meters Biopharma (NMTR), Akari Therapeutics (AKTX), Catalyst Biosciences (CBIO), Kazia Therapeutics (KZIA), LifeVantage (LFVN), Infinity Pharmaceuticals (INFI), Athenex (ATNX), Oncotelic Therapeutics (OTLC), iBio (IBIO), eFFECTOR Therapeutics (EFTR), Frequency Therapeutics (FREQ), DiaMedica Therapeutics (DMAC), Oncternal Therapeutics (ONCT), Processa Pharmaceuticals (PCSA) and SELLAS Life Sciences Group (SLS). View all of DFFN's competitors. What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF). What is Diffusion Pharmaceuticals' stock symbol? Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN." How do I buy shares of Diffusion Pharmaceuticals? Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Diffusion Pharmaceuticals' stock price today? One share of DFFN stock can currently be purchased for approximately $6.89. How much money does Diffusion Pharmaceuticals make? Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $14.06 million. The company earns $-24,100,000.00 in net income (profit) each year or ($12.22) on an earnings per share basis. How many employees does Diffusion Pharmaceuticals have? Diffusion Pharmaceuticals employs 16 workers across the globe. How can I contact Diffusion Pharmaceuticals? Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722. This page (NASDAQ:DFFN) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here